Dr Edwin Moses

After completing his post-doctoral research in Germany, Edwin began a commercial career with successful periods spent at Amersham International, Enzymatix and Raggio-Italgene. From 1993-2001 as CEO and then Chairman he was responsible for the growth of Oxford Asymmetry (OAI) through a series of venture rounds cumulating in a floatation (LSE) in 1998 at a value of €175M (£120M) followed by a sale of the company to Evotec Biosystems in 2000 for €460M (£316M). During this period, OAI grew from four people to over 250. Over the past five years Edwin has played an important role at Board level (primarily as Chairman) in over 15 European life science companies. During this time he has been involved in financing rounds totaling in excess of €200M, a series of M&A transactions and three IPO’s. In March 2006, Edwin accepted the offer by Ablynx’s Board to extend his role as Chairman to include that of Chief Executive Officer. Edwin has been Chairman of Ablynx since 2004.